Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03535740
Title	A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)
Acronym	ALTA-2
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Ariad Pharmaceuticals
Indications	lung non-small cell carcinoma
Therapies	Brigatinib
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| AUT \| AUS